Early reports demonstrated that the AR degradation enhancer ASC-J9 could suppress AR-mediated diseases, such as liver cancer (12), bladder cancer (13), prostate cancer (45), and spinal and bulbar muscular atrophy (15). This evidence concerns the gene AR and prostate cancer.